SCHEMBL2182998

SCHEMBL2182998

Clc1cc(Cl)cc(OCc2ccno2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
HDAC1 Q13547 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SOD1 P00441 1/20 0.39
CYP2C19 P33261 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.38
MAPT P10636 5/20 0.38
KDM4C Q9H3R0 1/20 0.37
POLB P06746 1/20 0.35
CHRNB2 P17787 1/20 0.34
CHRNB4 P30926 1/20 0.34
CHRNA3 P32297 1/20 0.34
CHRNA4 P43681 1/20 0.34
CHRNA2 Q15822 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6002649 0.77 RAB9A (0.51) L3MBTL1TDP1MEN1KMT2ARAB9A
SCHEMBL20020407 0.71 MEN1 (0.41) MEN1KMT2ASMN1; SMN2NOTUM
SCHEMBL23657823 0.71 RAB9A (0.51) L3MBTL1TDP1MEN1KMT2ARAB9A
SCHEMBL28215465 0.67 SMN1; SMN2 (0.53) MEN1KMT2ARAB9ASMN1; SMN2MRGPRX4
SCHEMBL13321691 0.66 MAOB (0.60) MRGPRX4
Hydrochloric Acid SCHEMBL8873563 0.66
SCHEMBL17321304 0.64 NOTUM (0.48) L3MBTL1KMT2ARAB9ACYP2C19NOTUM
SCHEMBL4933216 0.64 MRGPRX4 (0.63) L3MBTL1HDAC6MEN1KMT2ARAB9A
SCHEMBL2098196 0.64
SCHEMBL28049587 0.64 GRM5 (0.53) MEN1KMT2ASMN1; SMN2MRGPRX4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9949980-B2 Drugs to prevent HPV infection WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2018-04-24 US disclosed
US-20150297602-A1 DRUGS TO PREVENT HPV INFECTION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-22 US disclosed
US-9066951-B2 Drugs to treat HPV infection WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2015-06-30 US disclosed
US-20110165220-A1 DRUGS TO PREVENT HPV INFECTION WISCONSIN ALUMNI RESEARCH FOUNDATION 2011-07-07 US disclosed
WO-2009148961-A2 DRUGS TO PREVENT HPV INFECTION WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2009-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110165220-A1 DRUGS TO PREVENT HPV INFECTION VHL, PHF13, CDKN1A L3MBTL1 2983/4885TDP1 1975/4885HDAC1 2377/4885
US-20150297602-A1 DRUGS TO PREVENT HPV INFECTION VHL, PHF13, CDKN1A L3MBTL1 2983/4885TDP1 1975/4885HDAC1 2377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.